Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia

Heart and Vessels

Volumn 20, Issue 1, 2005, Pages 8-12

  Matsuo, Takashi ^a,c   Iwade, Kazunori ^a   Hirata, Naomi ^a   Yamashita, Michio ^a   Ikegami, Haruhiko ^a   Tanaka, Naohide ^a   Aosaki, Masahiko ^a   Kasanuki, Hiroshi ^b  

^a NATIONAL HOSPITAL ORGANIZATION YOKOHAMA MEDICAL CENTER   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Kosei Hospital   (Japan)

Author keywords

Arterial stiffness; Hypercholesterolemia; Statin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TRIACYLGLYCEROL;

ADULT; AGED; ANKLE BRACHIAL INDEX; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; MEASUREMENT; MEDICAL INSTRUMENTATION; OXIDATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RIGIDITY; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; AGED; ANTIOXIDANTS; ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; PYRIDINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATION;

EID: 13844307654     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-004-0793-5     Document Type: Article

References (19)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
3. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
4. WOSCOPS Study Group (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445
5. Laufs U, La Fata V, Liao JK (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725-31729
6. Yoshida M, Sawasa T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA Jr, Yasukochi Y, Numano F (2001) HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 21:1165-1171
7. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M (2000) Improvement of nitric oxide-dependent vasodilation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69
8. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A (2001) Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 104:376-379
9. Yasunobu Y, Hayashi K, Shingu T, Nomura K, Ohkura Y, Tanaka K, Kuga Y, Nomura S, Ohtani H, Nishimura T, Matsuura H, Kajiyama G (1997) Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs. Cardiovasc Drugs Ther 11:567-574
10. Committee on Guidelines for the Treatment of Hyperlipidemia of the Japan Arteriosclerosis Society (1997) Guidelines for treatment of hyperlipidemia. J Jpn Arterioscler 25:1-34
11. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A (2001) Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 89:415-421
12. Morishita R (2000) Encouragement of studies on statins, aiming at flexible blood vessels. Vasc Med 1:79-85
13. Mosti G, Iabichella ML, Picerni P (2000) Pulse wave velocity. A new calculation method. Minerva Cardioangiol 48:53-59
14. Asmar R, Rudnichi A, Blacher J, London GM, Safar ME (2001) Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populations. Am J Hypertens 14:91-97
15. Harada A, Okada T, Niki K, Chang D, Sugawara M (2002) Online noninvasive one-point measurement of pulse wave velocity. Heart Vessels 17:61-68
16. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM (2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103:987-992
17. Naito M, Yamada K, Hayashi T, Asai K, Yoshimine N, Iguchi A (1994) Comparative toxicity of oxidatively modified low-density lipoprotein and lysophosphatidylcholine in cultured vascular endothelial cells. Heart Vessels 9:183-187
18. Tokac M, Ozeren A, Aktan M, Altunkeser BB, Ozdemir K, Duzenli A, Gok H (2003) The role of inflammation markers in triggering acute coronary events. Heart Vessels 18:171-176
19. Saito Y, Shirai K, Uchino J, Okazawa M, Hattori Y, Yoshida T, Yoshida S (1990) Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients - 2-year trial. Cardiovasc Drugs Ther 4(suppl 5):987-990